Compare Amgen, Inc. (AMGN) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Deckers Outdoor Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Deckers Outdoor Corp trades at $106.51 (market cap $14.72B). The key difference: Amgen, Inc. is far larger — about 13.3× Deckers Outdoor Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.
| AMGN | DECK | |
|---|---|---|
Market Cap | $196.12B | $14.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $123.91 |
52-Week Low | $271.18 | $79.54 |
Enterprise Value | $241.41B | $13.19B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DECK trades at $105.99, up 1.66% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.99B in 2025, with net income reaching $966M and profit margin expanding to 19.37%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.96 versus $0.83 expected. Cash flow from operations remains robust at $1.04B, supporting financial stability.
The stock offers upside to the $121.50 consensus price target, driven by HOKA and UGG global growth. Risks include competitive pressures and volatile technical indicators. Analyst sentiment is mixed with 41.82% buy ratings, but institutional holdings suggest long-term confidence amid near-term bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
